Clinical Study of Glaukos® Trabecular Micro-Bypass System Model iS3 Infinite Vs. Competitor

NCT05127551 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 179

Last updated 2024-08-15

No results posted yet for this study

Summary

A study of the iStent Infinite product in the treatment of open-angle glaucoma vs competitor

Conditions

Interventions

DEVICE

iStent Infinite

Implantation of the iStent Infinite

DEVICE

Competitor Device

Implantation of competitor device

Sponsors & Collaborators

  • Glaukos Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-27
Primary Completion
2024-02-29
Completion
2025-02-28
FDA Device
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05127551 on ClinicalTrials.gov